Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06219941 · ClinicalTrials.gov registry record · Phase 2

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

A Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 2
Development phase
224
Enrollment target
20
Study locations

NCT06219941 is a Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 224 participants, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (30% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06219941, a Phase 2 study of Gastric Cancer and Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 2
Development phase
224 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

Conditions Studied

Gastric Cancer Pancreatic Ductal Adenocarcinoma Biliary Tract Cancer Gastroesophageal-junction Cancer

Interventions

  • DRUG Leucovorin
  • DRUG Irinotecan
  • DRUG 5-Fluorouracil
  • DRUG AZD0901
  • DRUG l-leucovorin

Study Locations (20)

Other

  • Research Site - Melbourne
  • Research Site - Murdoch
  • Research Site - Randwick
  • Research Site - Changsha
  • Research Site - Chengdu
  • Research Site - Tbilisi
  • Research Site - Chūōku
  • Research Site - Kashiwa
  • Research Site - Kitaadachi-gun

California

  • Research Site - Orange
  • Research Site - Palo Alto
  • Research Site - Santa Rosa

Ontario

  • Research Site - Kingston
  • Research Site - Toronto

Quebec

  • Research Site - Montreal
  • Research Site - Sherbrooke

Kentucky

  • Research Site - Louisville

New York

  • Research Site - Commack

Rhode Island

  • Research Site - Providence

Texas

  • Research Site - Houston

Trial Details

FieldValue
Enrollment Target 224 participants
Start Date 2023-12-13
Est. Completion 2027-09-30
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06219941

The ClinicalTrials.gov registry entry for NCT06219941 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 318-participant average among 153 other Gastric Cancer trials with a reported enrollment target (30% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Leucovorin is the first listed.

NCT06219941 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, California, Ontario.

Frequently Asked Questions

What is clinical trial NCT06219941 about?

NCT06219941 is a clinical study titled "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2". The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participants with locally advanced unresectable or metastatic solid tumours expressing CLDN18.2.

What is the current status of trial NCT06219941?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2023-12-13. Estimated completion is 2027-09-30.

What conditions does trial NCT06219941 study?

This clinical trial studies the following conditions: Gastric Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer, Gastroesophageal-junction Cancer.

What interventions are being tested in trial NCT06219941?

The interventions under investigation include: Leucovorin (DRUG), Irinotecan (DRUG), 5-Fluorouracil (DRUG), AZD0901 (DRUG), l-leucovorin (DRUG).

Who is sponsoring clinical trial NCT06219941?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06219941 being conducted?

This trial has 20 study locations across California, Kentucky, New York, Rhode Island, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Gastric Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Gastric Cancer

All registered trials for this condition

Pancreatic Ductal Adenocarcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.